Related Experiment Video
Updated: Jun 23, 2026

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
Published on: September 13, 2019
Rhabdomyosarcoma in children
Andrea Hayes-Jordan1, Richard Andrassy
1University of Texas MD Anderson Cancer Center, University of Texas Houston Health Sciences Center, Houston, TX 77030, USA. ahjordan@mdanderson.org
Insights
This review details the diagnosis, assessment, and treatment of rhabdomyosarcoma, a rare childhood cancer. It highlights a new risk classification system improving survival rates for affected children.
Area of Science:
- Pediatric Oncology
- Cancer Research
- Rare Diseases
Background:
- Rhabdomyosarcoma is a rare pediatric malignancy affecting approximately 300 children annually in the US.
- Accurate diagnosis and timely treatment are crucial for improving patient outcomes.
Purpose of the Study:
- To enhance understanding of the complex diagnosis, assessment, and treatment of pediatric rhabdomyosarcoma.
- To serve as a reference for practitioners encountering suspected cases in children.
Main Methods:
- Review of current literature and clinical protocols.
- Focus on the Children's Oncology Group's new risk classification system.
- Compilation of essential diagnostic tests and imaging modalities.
Main Results:
- Introduction of a new risk classification (low, intermediate, high) replacing previous staging and grouping.
- Identification of diagnostic criteria and imaging requirements for rhabdomyosarcoma.
- Demonstration of significant survival improvements over the past 25 years.
Conclusions:
- The new risk classification is foundational for current rhabdomyosarcoma treatment protocols.
- Rapid diagnosis and appropriate management are key to improving long-term survival.
- Overall survival for rhabdomyosarcoma has reached 70%, with some sites achieving up to 90% survival.
Purpose Of Review:
Rhabdomyosarcoma is a rare childhood cancer that affects only approximately 300 children per year in the United States. The purpose of this review is to provide the reader a greater understanding of the complex diagnosis, assessment and treatment of rhabdomyosarcoma in children.
Recent Findings:
This review focuses on the new risk classification that is the foundation of all present rhabdomyosarcoma protocols developed by the Children's Oncology Group of the United States and Canada. The new risk classification of low, intermediate and high encompasses the staging and grouping categories that were previously utilized.
Summary:
This review also provides a complete list of diagnostic tests and imaging required to identify rhabdomyosarcoma in any body site. Rapid diagnosis and recognition of this rare disorder will facilitate long-term survival. Rhabdomyosarcoma today has an overall survival of 70%, depending on the site, and in orbital and other sites survival is as high as 90%. The treatment approaches that have led to this doubling in survival over the last 25 years are reviewed. For a practitioner, this review can be used as a reference when a child with a suspicious mass is encountered.
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Satellite Stem Cells and Muscular Dystrophy
Abnormal Proliferation
